During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma and evaluated the findings on dual immunotherapy in this setting.
First-Line Treatment Using Combination Therapy in Advanced RCC
During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens for non–clear cell renal cell carcinoma.
During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on current data and particular challenges facing patients.
During a live event, Randy F. Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.
During a live event, Nataliya Mar, MD, discussed a non–clear cell renal cell carcinoma trial of cabozantinib/nivolumab and how it compares to other combinations.
During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.
In this Q&A discussion, Hans Hammers, MD, PhD, explains the rationale for continued use of tyrosine kinase inhibitor and PD-L1 therapy combinations, like lenvatinib and pembrolizumab, for patients with advanced renal cell carcinoma.
During a live virtual event, Sarah Yenser Wood, RN, MSN, ANP, AOCNP, and a panel of oncology nurses discussed their approaches to management of patients receiving first-line regimens for advanced or metastatic renal cell carcinoma.
Pedro C. Barata, MD, MSc, explains how the favorable efficacy and tolerability of lenvatinib and pembrolizumab observed in the CLEAR trial helps provide a standard of care in this patient population.
During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed with participants their experiences managing toxicities of frontline combination therapy for renal cell carcinoma. This is the second of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed the factors influencing the choice of frontline therapy for a patient with stage IV clear cell renal cell carcinoma whose risk status was intermediate.
During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed with participants their experiences using lenvatinib in treatment of advanced renal cell carcinoma. This is the second of 2 articles based on this event.
During a live virtual event, Robert J. Motzer, MD, discussed the role of risk assessment in treating a patient with clear cell renal cell carcinoma. This is the first of 2 articles based on this event.
During a live virtual event, Thomas Hutson, DO, PharmD, discussed the outcomes of the CLEAR trial of lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma.
During a live virtual event, Thomas Hutson, MD, PharmD, discussed the 4 frontline combination regimens including immunotherapies and tyrosine kinase inhibitors. This is the first of 2 articles based on this live event.
During a live virtual event, Brian Rini, MD, discussed how the combination of cabozantinib plus nivolumab compares with lenvatinib plus pembrolizumab in terms of tolerability and management in patients with advanced renal cell carcinoma.
During a live virtual event, Brian Rini, MD, discussed the efficacy and tolerability of approved first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced renal cell carcinoma.
Thomas Hutson, MD, PharmD, discusses management strategies when confronting adverse events using combination therapies in treating patients with renal cell carcinoma.
During a live virtual event, Nicholas J. Vogelzang, MD, discussed the results of the CLEAR trial of lenvatinib for patients with advanced renal cell carcinoma.
During a live virtual event, Moshe Ornstein, MD, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and participants' experiences with these agents.
During a live virtual event, Ulka Vaishampayan, MBBS, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab compared with sunitinib in first-line treatment of advanced RCC.
During a live virtual event, Sandy Srinivas, MD, discussed the tolerability of the tyrosine kinase inhibitor/immunotherapy combinations cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, compared with the dual immunotherapy ipilimumab plus nivolumab.
During a live virtual event, Sandy Srinivas, MD, discussed results from the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and the participants' experiences with the regimen including dose reductions needed by their patients across multiple cancer types.